2,279 reports of this reaction
2.1% of all ETONOGESTREL reports
#15 most reported adverse reaction
VAGINAL HAEMORRHAGE is the #15 most commonly reported adverse reaction for ETONOGESTREL, manufactured by Organon LLC. There are 2,279 FDA adverse event reports linking ETONOGESTREL to VAGINAL HAEMORRHAGE. This represents approximately 2.1% of all 110,074 adverse event reports for this drug.
Patients taking ETONOGESTREL who experience vaginal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VAGINAL HAEMORRHAGE is a less commonly reported adverse event for ETONOGESTREL, but still significant enough to appear in the safety profile.
In addition to vaginal haemorrhage, the following adverse reactions have been reported for ETONOGESTREL:
The following drugs have also been linked to vaginal haemorrhage in FDA adverse event reports:
VAGINAL HAEMORRHAGE has been reported as an adverse event in 2,279 FDA reports for ETONOGESTREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
VAGINAL HAEMORRHAGE accounts for approximately 2.1% of all adverse event reports for ETONOGESTREL, making it a notable side effect.
If you experience vaginal haemorrhage while taking ETONOGESTREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.